SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-18-048818
Filing Date
2018-08-01
Accepted
2018-08-01 17:16:34
Documents
5
Period of Report
2018-07-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a18-17513_108k.htm 8-K 27696
2 EX-1.1 a18-17513_10ex1d1.htm EX-1.1 268418
3 EX-5.1 a18-17513_10ex5d1.htm EX-5.1 21367
4 EX-99.1 a18-17513_10ex99d1.htm EX-99.1 10313
5 GRAPHIC g1751310kii001.gif GRAPHIC 2127
  Complete submission text file 0001104659-18-048818.txt   332122
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 18985765
SIC: 2834 Pharmaceutical Preparations